XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Gravina, Giovanni Luca ^a,c   Tortoreto, Monica ^b   Mancini, Andrea ^a   Addis, Alessandro ^b   Di Cesare, Ernesto ^a   Lenzi, Andrea ^c   Landesman, Yosef ^d   McCauley, Dilara ^d   Kauffman, Michael ^d   Shacham, Sharon ^d   Zaffaroni, Nadia ^b   Festuccia, Claudio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Karyopharm Therapeutics   (United States)

Author keywords

Bone metastases; CRM1; KPT 330; Prostate cancer; Selinexor; Tumor suppressor protein; XPO1

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMOSOME REGION MAINTENANCE 1; CYTOKINE; EXPORTIN 1; KPT 251; PROTEINASE; SELINEXOR; UNCLASSIFIED DRUG; CELL RECEPTOR; EXPORTIN 1 PROTEIN; HYDRAZINE DERIVATIVE; KARYOPHERIN; KPT-330; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE LESION; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; DRUG POTENCY; ENZYME RELEASE; HYPOTHESIS; IN VITRO STUDY; LYSIS; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OVERALL SURVIVAL; PROSTATE CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VISCERAL METASTASIS; ACTIVE TRANSPORT; ANIMAL; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; METASTASIS; OSTEOBLAST; PATHOLOGY; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; HYDRAZINES; KARYOPHERINS; MALE; MICE, SCID; NEOPLASM METASTASIS; OSTEOBLASTS; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907934952     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-46     Document Type: Article

References (59)

1. Estimates of cancer incidence and mortality in Europe in 2008. Ferlay J, Parkin DM, Steliarova-Foucher E, Eur J Cancer 2010 46 765 781 10.1016/j.ejca.2009.12.014 20116997
2. Biology and clinical management of prostate cancer bone metastasis. Ye XC, Choueiri M, Tu SM, Lin SH, Front Biosci 2007 12 3273 3286 10.2741/2311 17485298
3. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration. Schmitz-Dräger BJ, Weiss C, Ebert T, Dörsam J, Bismarck E, Urol Int 2013 90 329 333 10.1159/000346387 23407093
4. Denosumab: a new option in the treatment of bone metastases from urological cancers. Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J, Onco Targets Ther 2012 5 221 229 23055747
5. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. El-Amm J, Freeman A, Patel N, Aragon-Ching JB, Prostate Cancer 2013 27 2357 2365 review
6. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A, Cell Death Dis 2013 23 4 641
7. The XPO1 nuclear export protein in normal development and disease. Nguyen KT, Holloway MP, Altura RA, Int J Biochem Mol Biol 2012 3 137 151 22773955
8. Nuclear export of proteins and drug resistance in cancer. Turner JG, Dawson J, Sullivan DM, Biochem Pharmacol 2012 83 1021 1032 10.1016/j.bcp.2011.12.016 22209898
9. Nuclear export mediated regulation of MicroRNAs: potential target for drug intervention. Muqbil I, Bao B, Abou-Samra AB, Mohammad RM, Azmi AS, Curr Drug Targets 2013 14 1094 1100 10.2174/1389450111314100002 23834155
10. mRNA export and cancer. Siddiqui N, Borden KL, Wiley Interdiscip Rev RNA 2012 3 13 25 10.1002/wrna.101 21796793
11. Characterization of BARD1 targeting and dynamics at the centrosome: the role of XPO1, BRCA1 and the Q564H mutation. Brodie KM, Mok MT, Henderson BR, Cell Signal 2012 24 451 459 10.1016/j.cellsig.2011.09.024 21982881
12. p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor XPO1. Santiago A, Li D, Zhao LY, Godsey A, Liao D, Mol Biol Cell 2013 24 2739 2752 10.1091/mbc.E12-10-0771 23825024
13. Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, XPO1, and Aurora A kinase. Brodie KM, Henderson BR, J Biol Chem 2012 287 7701 7716 10.1074/jbc.M111.327296 22262852
14. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Chan KS, Wong CH, Huang YF, Li HY, Cell Death Dis 2010 1 57 10.1038/cddis.2010.34 21364662
15. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. Mariano AR, Colombo E, Luzi L, Martinelli P, Volorio S, Bernard L, Meani N, Bergomas R, Alcalay M, Pelicci PG, Oncogene 2006 25 4376 4380 10.1038/sj.onc.1209453 16501600
16. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Henderson BR, Nat Cell Biol 2000 2 653 660 10.1038/35023605 10980707
17. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC, Blood 2012 120 4621 4634 10.1182/blood-2012-05-429506 23034282
18. Weiss RH.CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, J Urol 2013 189 2317 2326 10.1016/j.juro.2012.10.018 23079374
19. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV, Exp Hematol 2013 41 67 78 10.1016/j.exphem.2012.09.002 22986101
20. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC, Mol Cancer Ther 2013 12 1171 1179 10.1158/1535-7163.MCT-12-1171 23615632
21. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM, Gastroenterology 2013 144 447 456 10.1053/j.gastro.2012.10.036 23089203
22. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR, Cancer Chemother Pharmacol 1986 16 95 101 3081269
23. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB, Murli S, Cancer Res 2009 69 510 517 10.1158/0008-5472.CAN-08-0858 19147564
24. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK, Leukemia 2013 Jun 11
25. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas LA, Br J Haematol 2013 161 117 127 10.1111/bjh.12231 23373539
26. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R, Blood 2012 120 1765 1773 10.1182/blood-2012-04-423160 22677130
27. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, Look AT, Leukemia 2013 27 66 74 10.1038/leu.2012.219 22847027
28. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, Löwik CW, van der Pluijm G, Am J Pathol 2007 171 1047 1057 10.2353/ajpath.2007.070168 17724140
29. Evaluation of metastatic potential in prostate carcinoma: an in vivo model. Angelucci A, Gravina GL, Rucci N, Festuccia C, Muzi P, Vicentini C, Teti A, Bologna M, Int J Oncol 2004 25 1713 1720 15547709
30. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C, Bologna M, Endocr Relat Cancer 2006 13 197 210 10.1677/erc.1.01100 16601288
31. In vivo models of prostate cancer metastasis to bone. Singh AS, Figg WD, J Urol 2005 174 820 826 10.1097/01.ju.0000169133.82167.aa 16093963
32. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Park SI, Kim SJ, McCauley LK, Gallick GE, Curr Protoc Pharmacol 2010 14 Unit 14.15. doi: 10.1002/0471141755.ph1415s51.
33. RANKL up-regulates brain-type creatine kinase via poly (ADP-ribose) polymerase-1 during osteoclastogenesis. Chen J, Sun Y, Mao X, Liu Q, Wu H, Chen Y, J Biol Chem 2010 285 36315 36321 10.1074/jbc.M110.157743 20837480
34. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C, Bologna M, Int J Oncol 2007 30 193 200 17143529
35. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Festuccia C, Vincentini C, di Pasquale AB, Aceto G, Zazzeroni F, Miano L, Bologna M, Oncol Res 1995 7 131 138 8555646
36. Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagement. Festuccia C, Angelucci A, Gravina G, Eleuterio E, Vicentini C, Bologna M, Exp Cell Res 2002 280 1 11 10.1006/excr.2002.5609 12372334
37. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. Stephenson RA, Dinney CP, Gohji K, Ordóñez NG, Killion JJ, Fidler IJ, J Natl Cancer Inst 1992 17 84 951 957
38. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Salerno M1, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, Micieli D, Pignatello R, Capulli M, Rucci N, Angelucci A, Del Fattore A, Teti A, Zini N, Giunti A, Baldini N, Curr Cancer Drug Targets 2010 10 649 659 10.2174/156800910793605767 20578992
39. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL, Prostate 2002 52 20 33 10.1002/pros.10091 11992617
40. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Yang M, Burton DW, Geller J, Hillegonds DJ, Hastings RH, Deftos LJ, Hoffman RM, Clin Cancer Res 2006 12 2602 2606 10.1158/1078-0432.CCR-05-2050 16638872
41. Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines. Perez M, Migliaccio S, Taranta A, Festuccia C, Orrù L, Brama M, Bologna M, Faraggiana T, Baron R, Teti A, Eur J Cancer 2001 37 629 640 10.1016/S0959-8049(00)00436-6 11290439
42. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V, Cancer Res 2010 70 6150 6160 10.1158/0008-5472.CAN-09-2758 20631064
43. Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. Tuomela JM, Valta MP, Väänänen K, Härkönen PL, BMC Cancer 2008 8 81 10.1186/1471-2407-8-81 18371232
44. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS, J Biol Chem 2005 280 36529 36540 10.1074/jbc.M503111200 16127174
45. Prelinical evaluation of selective inhibitors of nuclear export (SINE) XPO1 (XPO1) inhibitors in prostate cancer (PrCa) Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: JUN 01-06, 2012 Sponsor(s): Amer Soc Clin Oncol (ASCO). Shacham S, Gravina GL, Ricevuto E, Mancini A, Chin L, Shechter S, Sandanayaka V, McCauley D, Kauffman M, Festuccia C, J Clin Oncol 2012 30 15 Supplement 15200 Meeting Abstract
46. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models. Gravina GL, Marampon F, Sherris D, Vittorini F, Cesare ED, Tombolini V, Lenzi A, Jannini EA, Festuccia C, Prostate 2014 74 852 868 10.1002/pros.22804 24715588
47. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Gravina GL, Marampon F, Muzi P, Mancini A, Piccolella M, Negri-Cesi P, Motta M, Lenzi A, Di Cesare E, Tombolini V, Jannini EA, Festuccia C, Endocr Relat Cancer 2013 20 321 337 10.1530/ERC-12-0240 23507703
48. Genes associate with abnormal bone cell activity in bone metastasis. Roodman GD, Cancer Metastasis Rev 2012 31 569 578 10.1007/s10555-012-9372-x 22706844
49. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Yoneda T, Hiraga T, Biochem Biophys Res Commun 2005 328 679 687 Review 10.1016/j.bbrc.2004.11.070 15694401
50. The role of p27(Kip1) phosphorylation at serine 10 in the migration of malignant glioma cells in vitro. Wang D, He F, Zhang L, Zhang F, Wang Q, Qian X, Pan X, Meng J, Peng C, Shen A, Chen J, Neoplasma 2011 58 65 73 21067268
51. Modulation of integrin-linked kinase nucleo-cytoplasmic shuttling by ILKAP and XPO1. Nakrieko KA, Vespa A, Mason D, Irvine TS, D'Souza SJ, Dagnino L, Cell Cycle 2008 7 2157 2166 10.4161/cc.7.14.6241 18635968
52. Nucleo-cytoplasmic shuttling of PAK4 modulates β-catenin intracellular translocation and signaling. Li Y, Shao Y, Tong Y, Shen T, Zhang J, Li Y, Gu H, Li F, Biochim Biophys Acta 1823 2012 465 475
53. Normalization and subtraction: two approaches to facilitate gene discovery. Bonaldo MF, Lennon G, Soares MB, Genome Res 1997 6 791 806
54. Leptomycin B reduces matrix metalloproteinase-9 expression and suppresses cutaneous inflammation. Kobayashi T, Shinkai H, J Invest Dermatol 2005 124 331 337 10.1111/j.0022-202X.2004.23595.x 15675951
55. Antagonistic functions of tetradecanoyl phorbol acetate-inducible-sequence 11b and HuR in the hormonal regulation of vascular endothelial growth factor messenger ribonucleic acid stability by adrenocorticotropin. Cherradi N, Lejczak C, Desroches-Castan A, Feige JJ, Mol Endocrinol 2006 20 916 930 10.1210/me.2005-0121 16306087
56. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz AK, Brody JR, PLoS One 2010 5 15455 10.1371/journal.pone.0015455 21152064
57. Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases. López-Carrizosa MC, Samper-Ots PM, Pérez AR, Clin Transl Oncol 2010 12 568 573 10.1007/s12094-010-0555-z 20709654
58. XPO1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC, Leukemia 2013 28 155 165 23588715
59. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma. Festuccia C, Teti A, Bianco P, Guerra F, Vicentini C, Tennina R, Villanova I, Sciortino G, Bologna M, Oncol Res 1997 9 419 431 9436195